Login to Your Account



CTI: Tosedostat on Partial Hold After Death of Patient in Trial

By Randy Osborne
Staff Writer

Monday, June 24, 2013
The death of a patient in trials with tosedostat for blood-related cancer cast a pall over Cell Therapeutics Inc.'s shares when investors learned of the partial clinical hold, placed on the compound June 17.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription